Apparent beneficial effects of tamoxifen on bone mineral content in patients with breast cancer: preliminary study.
Eight postmenopausal women undergoing adjuvant treatment with tamoxifen (20 mg/day) for breast cancer had baseline pretreatment, and 6- and 12-month post-treatment dual-photon determinations of vertebral bone mineral content (BMC). BMC measured at 6 and 12 months increased over baseline in all subjects. These observations imply that women treated with tamoxifen may retain rather than surrender the protective effect of estrogen against osteoporosis.
Ryan
W G
WG
Rush-Presbyterian-St Luke's Medical Center, Chicago, Illinois 60612.
Wolter
J
J
Bagdade
J D
JD
D000368:Aged; D015519:Bone Density / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D013629:Tamoxifen / Q000627:therapeutic use*
D013629:Tamoxifen